Insider Trading Alert - IPXL, SNCR, CYBX, KLIC And SPW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 8, 2014, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,000.20 to $12,860,510.00.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Burr Robert L who is Director at Impax Laboratories sold 1,500 shares at $24.31 on Jan. 8, 2014. Following this transaction, the Director owned 43,825 shares meaning that the stake was reduced by 3.31% with the 1,500-share transaction.

The shares most recently traded at $24.49, up $0.18, or 0.73% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 3,000
  • 24-Week # shares sold: 7,500

The average volume for Impax Laboratories has been 468,300 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.7 billion and is part of the health care sector and drugs industry. Shares are down 2.35% year-to-date as of the close of trading on Wednesday.

Impax Laboratories, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and marketing of bioequivalent pharmaceutical products; and development and marketing of branded products. The company has a P/E ratio of 14.5. Currently there are 3 analysts that rate Impax Laboratories a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Impax Shares Jump on Merger Buzz

Impax Shares Jump After Chinese Firm Reveals 5% Stake

Teva, Mylan Seen to Stay on M&A Sidelines

Teva's Massive Debt Load Just Became an Even Bigger Issue

Teva Shares Are Getting Obliterated Again After Vicious Investment Bank Downgrades